LynkuetTM (elinzanetant) receives first global approval in UK for moderate to severe menopause-related hot flashes, based on OASIS trials. It's the first dual neurokinin-targeted therapy.

BlueRock’s OpCT-001, the first iPSC-derived therapy for photoreceptor diseases, enters Phase 1/2a CLARICO trial to assess safety and impact on vision loss.

iCRO offers tailored services that support early research through Phase IV trials and Software as a Medical Device (SaMD) development for pharmaceutical, biotech, medical device, and digital health companies.

Bayer's Phase II panSOHO trial enrolls first patient to assess BAY 2927088 in HER2-mutant metastatic or unresectable tumors, including colorectal, uterine, bladder, and biliary cancers.

The company's pharma growth strategy advances with regulatory filings for key therapies, Phase III successes in oncology and radiology, and progress in gene therapy and precision oncology.

The REGENERATE-PD trial uses randomization and a double-blind design to evaluate AB-1005's efficacy and safety in treating moderate-stage Parkinson’s Disease, minimizing bias.

Bayer showcased tools for innovation in Radiology AI and digitalization and new collaborations in the area of AI at RSNA 2024.

Genvor will receive year-long access to lab space and equipment at Bayer’s LifeHub California @AgStart, one of the premier U.S. AgriFoodTech innovation ecosystems.

Bayer will present data on Kerendia™ (finerenone) use among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in real-world clinical practice, as well as new risk models for patients with CKD and T2D at the 61st European Renal Association (ERA) Congress.

Saudi launch aligns with Vision 2030 healthcare transformation strategy and highlights Huma and Bayer’s commitments to advancing care delivery in the Kingdom.